That title conjures up images of a bunch of drug mules with big backpacks of illegal drugs sneaking across the border under cover of darkness. However, in this context it is a large pipeline of new and novel drugs on their way through the testing stage before becoming the next big drug to fight cancer.
NEW BULLISH Plays
HALO - Halozyme Therapeutics - Company Profile
HALO is a biotechnology company that researches, develops and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company is also developing PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and other cancers in combination with various cancer therapies.
This is an easy play. The company is presenting data from multiple trials at the American Association of Cancer Research meeting that will take place April 17-20th. They will release five different abstracts detailing drug interactions at this conference. At the same time they will host an investor/analyst meeting on April 18th at 4:PM.
They reported earnings of 3 cents compares to expectations for a loss of 11 cents. Revenue was $52.2 million.
HALO has partnerships with Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly. This is not a pipsqueak company.
HALO broke over recent resistance at $11.25 on Wednesday and could run if the data presented is positive. I am recommending we take a long position with a tight stop at $10.50.
Buy HALO shares, initial stop loss $10.50.
No options recommended.
NEW BEARISH Plays
No New Bearish Plays